Disturbance of energy and redox homeostasis and reduction of Na+,K+-ATPase activity provoked by in vivo intracerebral administration of ethylmalonic acid to young rats  by Ritter, Luciana et al.
Biochimica et Biophysica Acta 1852 (2015) 759–767
Contents lists available at ScienceDirect
Biochimica et Biophysica Acta
j ourna l homepage: www.e lsev ie r .com/ locate /bbad isDisturbance of energy and redox homeostasis and reduction of
Na+,K+-ATPase activity provoked by in vivo intracerebral
administration of ethylmalonic acid to young ratsLuciana Ritter a, Daniele Kleemann a, Fernanda Hermes Hickmann a, Alexandre Umpierrez Amaral a,
Ângela Sitta b, Moacir Wajner a,b, César Augusto João Ribeiro a,⁎
a Departamento de Bioquímica, Instituto de Ciências Básicas da Saúde, Universidade Federal do Rio Grande do Sul, Porto Alegre, RS, Brazil
b Serviço de Genética Médica, Hospital de Clínicas de Porto Alegre, Porto Alegre, RS, BrazilAbbreviations: CAC, citric acid cycle; CK, creati
encephalopathy; EMA, ethylmalonic acid; ETC, electron
glutathione; MEL, melatonin; MDA, malondialdehyde
short chain acyl-CoAdehydrogenase; SCADD, short chain acy
⁎ Corresponding author at: Departamento de Bioquímic
da Saúde, Universidade Federal do Rio Grande do Sul, Port
Barcelos, 2600 – Anexo. Tel.: +55 51 33085572.
E-mail address: cesar.rib@gmail.com (C.A.J. Ribeiro).
http://dx.doi.org/10.1016/j.bbadis.2015.01.003
0925-4439/© 2015 Elsevier B.V. All rights reserved.a b s t r a c ta r t i c l e i n f oArticle history:
Received 20 August 2014
Received in revised form 4 January 2015
Accepted 6 January 2015
Available online 10 January 2015
Keywords:
Ethylmalonic acid
Energy metabolism
Redox homeostasis
Synaptic Na+,K+-ATPase
StriatumEthylmalonic acid (EMA) accumulation occurs in various metabolic diseases with neurological manifestation,
including short acyl-CoA dehydrogenase deﬁciency (SCADD) and ethylmalonic encephalopathy (EE). Since
pathophysiological mechanisms responsible for brain damage in these disorders are still poorly understood,
we investigated the ex vivo effects of acute intrastriatal administration of EMA on important parameters of
energy and redox homeostasis in striatum from young rats. We evaluated CO2 production from glucose, glucose
utilization and lactate production, as well as the activities of the citric acid cycle (CAC) enzymes, the electron
transfer chain (ETC) complexes II–IV (oxidative phosphorylation, OXPHOS) and synaptic Na+,K+-ATPase. We
also tested the effect of EMA on malondialdehyde (MDA) levels (marker of lipid oxidation) and reduced
glutathione (GSH) levels. EMA signiﬁcantly reduced CO2 production, increased glucose utilization and lactate
production, and reduced the activities of citrate synthase and of complexes II and II–III of the ETC, suggesting
an impairment of CAC andOXPHOS. EMA injection also reducedNa+,K+-ATPase activity andGSH concentrations,
whereas MDA levels were increased. Furthermore, EMA-induced diminution of Na+,K+-ATPase activity and
reduction of GSH levels were prevented, respectively, by the antioxidants melatonin and N-acetylcysteine,
indicating that reactive species were involved in these effects. Considering the importance of CAC and ETC for
energy production and Na+,K+-ATPase for the maintenance of the cell membrane potential, the present data
indicate that EMA compromises mitochondrial homeostasis and neurotransmission in striatum. We presume
that these pathomechanisms may be involved to a certain extent in the neurological damage found in patients
affected by SCADD and EE.
© 2015 Elsevier B.V. All rights reserved.1. Introduction
Increased levels of ethylmalonic acid (EMA) are observed in tissues
and body ﬂuids of patients with the metabolic disorders ethylmalonic
encephalopathy (EE, OMIM602473) and short-chain acyl-CoA dehydro-
genase deﬁciency (SCADD, OMIM 201470) [1–3]. Short chain acyl-CoA
dehydrogenase (SCAD) is a nuclear-encoded enzyme involved in degra-
dation of short-chain fatty acids in the mitochondrial β-oxidation path-
way [2]. Deﬁciency of SCAD activity leads to the accumulation of
butyryl-CoA, which is converted to EMA [4]. Although some affectedne kinase; EE, ethylmalonic
transfer chain; GSH, reduced
; NAC, N-acetylcysteine; SCAD,
l-CoAdehydrogenase deﬁciency
a, Instituto de Ciências Básicas e
o Alegre, RS, Brazil, Rua Ramiropatients are phenotypically normal, many of thempresent developmen-
tal delay, ketotic hypoglycemia, epilepsy, behavioral disorders, hypoto-
nia and seizures [2,5]. EE is caused by mutation in the ETHE1 gene and
is clinically characterized by early onset of acute encephalopathic crises,
neurological deterioration, chronic diarrhea, recurrent petechia and
orthostatic acrocyanosis leading to a fatal outcome in the ﬁrst years of
life [6]. The main consequence of ETHE1 loss is the accumulation of
hydrogen sulﬁde (H2S), which blocks short chain fatty acid metabolism
causing accumulation of EMA. Another interesting observation in
patients with these disorders is that they also accumulate and excrete
large amounts of lactic acid, suggesting mitochondrial dysfunction.
This hypothesis is supported by experimental studies performed in
the liver of SCAD deﬁcient mice showing multiple changes in energy
metabolism and in ﬁbroblasts from patients with SCAD deﬁciency
revealing alterations of redox status [2,7–9]. Indeed, various in vitro stud-
ies demonstrated that EMA provokes brain mitochondrial dysfunction. In
this regard, it was found that EMA inhibits creatine kinase activity and
induces lipid and protein oxidative damage in the cerebral cortex of rats
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EMA impairs mitochondrial succinate oxidation [13] and induces perme-
ability transition inmitochondria from rat brain [14]. Interestingly, chron-
ic administration of EMA during early life causes long-standing learning
and memory in adult rats [15], indicating that high persistent concentra-
tions of this organic acid disturb brain functioning that could be potential-
ly caused by impairment of mitochondrial homeostasis.
It is emphasized that these studies were essentially performed
in vitro and in the cerebral cortex and hippocampus. Since basal ganglia
abnormalities are observed in patients with ethylmalonic aciduria
[16–18] and, to the best of our knowledge, the in vivo effects of EMA
on brain bioenergetics and redox state have not yet been yet investigat-
ed, in the present study we evaluated the effects of intrastriatal EMA ad-
ministration on cell energy homeostasis and redox status in striatum
from young rats.We attempted tomimic the acute episodes of metabolic
decompensation that occur in patients affected by SCADD and EE, in
which elevated tissue concentrations of this toxic organic acid are associ-
ated with worsening of the neurological symptoms. The parameters ana-
lyzedwere 14CO2 production from [U-14C] glucose, glucoseutilization and
lactate production, the activities of citrate synthase, α-ketoglutarate
dehydrogenase, succinate dehydrogenase and malate dehydrogenase
(citric acid cycle), of the electron transfer chain complexes II–IV (oxida-
tive phosphorylation), of creatine kinase (intracellular ATP transfer)
and of synaptic Na+,K+-ATPase, an important enzyme necessary for
normal neurotransmission. We also tested the effect of EMA administra-
tion on the concentrations of reduced glutathione (GSH), an important
brain antioxidant defense, as well as on the levels of malondialdehyde,
a marker of lipid peroxidation, in rat striatum. We emphasize that our
present model does not substitute the genetic models of these disorders,
but rather serves to ﬁnd out acute deleterious effects of EMA.
2. Material and methods
2.1. Animals
Weused one hundred andﬁfteen 30-day-oldmaleWistar rats obtain-
ed from the Central Animal House of the Department of Biochemistry,
ICBS, UFRGS, in the assays. The animals had free access to water and to
a standard commercial chow and were maintained on a 12:12 h light/
dark cycle in an air-conditioned constant temperature (22± 1 °C) colony
room. The experimental protocol was approved by the Ethics Commit-
tee for Animal Research of the Universidade Federal do Rio Grande do
Sul, Porto Alegre, Brazil (protocol number 26123), and followed the
“Principles of Laboratory Animal Care” (NIH publication no. 80-23,
revised 1996). All effortsweremade tominimize the number of animals
and their suffering. All chemicals were purchased from Sigma Chemical
Co., St Louis, MO, USA.
2.2. Intrastriatal administration of ethylmalonic acid (EMA)
The rats were deeply anesthetized with ketamine plus xylazine and
placed on a stereotaxic apparatus. Two small holes were drilled in the
skull for microinjection. A single injection of EMA (0.75 or 1.5 μmol,
pH adjusted to 7.4 with NaOH) or NaCl (controls) at the same volume
and concentrations was bilaterally administered over 3 min via needles
connected by a polyethylene tube to a 25 μL Hamilton syringe. The
needles (one in each striatum) were left in place for another 1 min
before being softly removed. The coordinates for injections were as fol-
lows: 0.6 mm posterior to bregma, ±2.6 mm lateral to midline and
4.5 mm ventral from dura [19]. The correct position of the needle was
tested by injecting 0.5 μL of methylene blue injection (4% in saline
solution) followed by histological analysis. In some experiments mela-
tonin (MEL; 20 mg/kg, i.p.) or saline (0.9% i.p.) solutions were injected
and followed by EMA or NaCl injection [20]. In other experiments, the
animals were pre-treated daily for three days with one i.p. injection of
N-acetylcysteine (NAC; 150mg/kg) or saline (controls) [21]. Immediatelyafter the last injection (NAC or saline), the rats received an intrastriatal in-
jection of EMA or NaCl.
2.3. Striatal preparation
Rats were euthanized by decapitation without anesthesia 2 or 24 h
after EMA or NaCl intrastriatal administration. The brainwas immediate-
ly removed and kept on a Petri dish placed on ice, and the vessels and
blood removed. The striatum was dissected, weighed and kept chilled
until utilization. The striatum was cut into 400 μm slices, incubated in
Krebs–Ringer bicarbonate buffer, pH 7.4, and immediately used for
14CO2 formation, glucose utilization and lactate production. For the deter-
mination of the activities of the electron transfer chain complexes and
creatine kinase, the striatum was homogenized (1:20, w/v) in SETH
buffer, pH 7,4 (250 mM sucrose, 2.0 mM EDTA, 10 mM Trizma base
and 50 UI/mL heparin). The homogenate was centrifuged at 800 ×g for
10 min and the supernatant was kept at −70 °C until being used for
enzymatic activity determination.
Mitochondria from striatum were also prepared for the determina-
tion of citric acid cycle enzyme activities, as described by Rosenthal and
coworkers [22]. Brieﬂy, striatumwere homogenized 1:10 in ice-cold iso-
lation buffer containing 225 mMmannitol, 75 mM sucrose, 1 mM EGTA,
0.1% bovine serum albumin (BSA; fatty acid free), and 10 mM HEPES,
pH 7.2 in a glass homogenizer. The homogenate was centrifuged for
3 min at 2000 ×g. After centrifugation, the supernatant was centri-
fuged for 8 min at 12,000 ×g. The pellet containing mitochondria
was suspended in 20 mL of isolation buffer containing 20 μL of 10% digi-
tonin and centrifuged for 8 min at 12,000 ×g. The supernatant was
discarded and the ﬁnal pellet containing puriﬁed mitochondria gently
washed and suspended in isolation buffer devoid of EGTA, at an approxi-
mate protein concentration of 4mg/mL.Mitochondrial preparationswere
frozen at−70 °C until being used for enzymatic activity determination.
The period between tissue preparation andmeasurement of the var-
ious enzymatic activities was always less than 5 days, except for CO2
production, glucose consumption and lactate production assays, whose
experiments were performed in fresh preparations on the same day.
For the determination of reduced glutathione (GSH) and
malondialdehyde (MDA) concentrations, striatum obtained from rats
injectedwith EMA or NaCl were homogenized (1:10 w/v) in 20mM so-
dium phosphate buffer, pH 7.4, containing 140mMKCl and centrifuged
at 750 g for 10min at 4 °C to discard nuclei and cell debris [23]. The pel-
let was discarded and the supernatant, a suspension of mixed and pre-
served organelles, including mitochondria, was separated and used to
measure lipid peroxidation (MDA levels) and GSH concentrations [24].
For the isolation of synapticmembranes, striatumwas homogenized
in 10 volumes of 0.32 mM sucrose solution containing 5.0 mM HEPES
and 1.0 mM EDTA. Synaptical plasma membranes were prepared after-
wards according to the method of Jones and Matus [25] using a discon-
tinuous sucrose density gradient consisting of successive layers of 0.3,
0.8 and 1.0 M. After centrifugation at 69,000 ×g for 2 h, the fraction at
the 0.8–1.0 mM sucrose interface was taken as the synaptic membrane
preparation.
Supernatants from non-operated rat striatum were also prepared
from homogenates as described above. EMA (5 mM) was incubated
with these supernatants for 30 min at 37 °C to measure the activities
of CS and ETC complexes II and II–III.
2.4. Organic acid analysis
EMA quantiﬁcation was performed by gas chromatography/mass
spectrometry (GC/MS) according to Sweetman [26] with slight modiﬁca-
tions [27]. For this analysis, animals were euthanized 1 h after receiving a
single injection of EMA (0.75 μmol or 1.5 μmol, pH adjusted to 7.4 with
NaOH) or NaCl (controls). The striatum was homogenized (1:4, w/v) in
saline solution, pH 7.4, and an aliquot (300 μL) of striatal homogenate
was analyzed in a Varian Saturn 2000 GC/MS equipment. Each sample
Fig. 1. 14CO2 production from [U-14C] glucose in rat striatum 2 or 24 h after intrastriatal
injection of ethylmalonic acid (EMA, 1.5 μmol) or NaCl. Animals received NaCl or EMA into
each striatum as described in the Material and methods section. Values are mean ± SEM
for 4–5 independent experiments (animals) per group and expressed as pmol CO2/h/mg
tissue. *p b 0.05 compared to NaCl-injected rats (one-way ANOVA followed by the Duncan's
multiple range test).
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standard). A standard EMA solution (1.0 mM) was also submitted to the
same procedure and on the same day.
2.5. 14CO2 production
For CO2 production, 50 mg of striatal slices was added to small ﬂasks
(11 cm3), which were pre-warmed in a metabolic shaker at 37 °C for
10 min. After pre-warming, [U-14C] glucose (0.055 μCi) plus 5.0 mM of
unlabeled glucose were added to the incubation medium in a ﬁnal incu-
bation volume of 500 μL. The ﬂasks were gassed with a O2:CO2 (95:5)
mixture and sealed with rubber stoppers and paraﬁlm. Glass center
wells containing a folded 65 mm/5 mm piece of ﬁlter paper were hung
from the stoppers. After 60 min of incubation at 37 °C, 200 μL of 50% tri-
chloroacetic acid was added to the medium and 100 μL of benzethonium
hydroxide to the centerwellswithneedles introduced through the rubber
stopper. The ﬂasks were left to stand for 30 min to complete 14CO2 trap-
ping and then opened. The ﬁlter papers were removed and added to
vials containing scintillation ﬂuid, and radioactivity was measured [28].
Results correspond to pmol glucose oxidized/h/mg protein.
2.6. Glucose utilization and lactate production
For glucose utilization and lactate production, 50mg of striatal slices
was added to small ﬂasks (11 cm3), which were pre-incubated at 37 °C
for 15 min in Krebs–Ringer bicarbonate buffer, pH 7.4, followed by theFig. 2. Effect of intrastriatal administration of ethylmalonic acid (EMA, 1.5 μmol) on the activities o
B), succinate dehydrogenase (SDH, C) andmalate dehydrogenase (MDH, D) in rat striatum 2 or 24
and are expressed as nmol TNB/min/mg protein (CS), nmol NADH/min/mg protein (α-KDGH a
intrastriatal NaCl injection (one-way ANOVA followed by the Duncan's multiple range test).addition of 5mM glucose. After 60min incubation at 37 °C in ametabolic
shaker, an aliquot of the medium was collected for the determination of
glucose concentration and the reaction was stopped by the addition of
one volume of 0.6 N perchloric acid to the medium. Striatum slices were
then homogenized and the excess of perchloric acid was precipitated as
a potassium salt with the addition of one volume of 3M potassium bicar-
bonate. After centrifugation at 10,000 ×g for 5min at 4 °C, lactate concen-
trations were measured in the supernatant by the lactate peroxidase
method [29]. Glucose utilization was determined by the glucose oxidase
kit [30] and calculated by the difference between glucose concentration
at the beginning and at the end of incubation period. Results were
expressed as μmol of glucose/h/g tissue and μmol of lactate/h/g tissue.2.7. Citric acid cycle (CAC) enzyme activities
Citrate synthase (CS) activitywasmeasured according to Shepherd e
Garland [31], by determining DTNB reduction atλ=412 nm. The activ-
ity of α-ketoglutarate dehydrogenase (KGDH) complex was evaluated
according to Lai and Cooper [32], atwavelengths of excitation and emis-
sion of 340 and 466 nm, respectively. The activity of succinate dehydro-
genase (SDH)was determined as described by Fischer et al. [33]. Malate
dehydrogenase (MDH) activitywasmeasured according to Kitto [34] by
following the reduction of NADHatwavelengths of excitation and emis-
sion of 340 and 466 nm, respectively. The activities of the CAC enzymes
were expressed as nmol/min/mg protein, mmol/min/mg protein or
μmol/min/mg protein.2.8. Electron transfer chain complex II–IV activities
Activities of succinate-2,6-dichloroindophenol oxidoreductase (com-
plex II) and succinate: cytochrome c oxidoreductase (complex II–III)
were determined as described by Fischer et al. [33], whereas the activity
of cytochrome c oxidase (complex IV) was assayed by the method
described by Rustin and colleagues [35]. The techniques described
to measure these activities were slightlymodiﬁed, as described in details
in a previous report [36]. We applied approximately 0.01 to 0.1 mg
protein in the assays. These activities were expressed as nmol/min/mg
protein or mmol/min/mg protein.2.9. Creatine kinase activity
Creatine kinase (CK) activity was measured in total homogenates
according to Hughes [37] with slight modiﬁcations [38]. The creatine
formed was estimated according to the colorimetric method of Hughes
[37]. Results were expressed as μmol of creatine/min/mg protein.f citric acid cycle enzymes citrate synthase (CS, A),α-ketoglutarate dehydrogenase (α-KGDH,
h after EMA injection. Values are mean± SEM for 4–6 independent experiments (animals)
nd MDH), and nmol DCIP/min/mg protein (SDH). *p b 0.05 compared to rats that received
Fig. 3. Effect of intrastriatal administration of ethylmalonic acid (EMA, 1.5 μmol) on the activities of the respiratory chain complexes II–IV in rat striatum 2 or 24 h after EMA injection.
Values are mean ± SEM for 5–9 independent experiments (animals) per group. The activity of complex II (A) is expressed as nmol DCIP reduced min/mg protein. The activities of
complexes II–III (B) and IV (C) are expressed as nmol cytochrome c reduced min/mg protein and nmol cytochrome c oxidized min/mg protein respectively. *p b 0.05 compared to rats
that received intrastriatal NaCl injection (one-way ANOVA followed by the Duncan's multiple range test).
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Na+,K+-ATPase activity was determined according to Tsakiris and
Deliconstantinos [39], in a medium containing 5 mM MgCl2, 80 mM
NaCl, 20 mM KCl, 40 mM Tris–HCl buffer, pH 7.4, and puriﬁed striatal
synaptic membranes (approximately 20 μg protein) in a ﬁnal volume of
200 μl. The enzymatic assay occurred at 37 °C during 5 min and started
by the addition of ATP to a ﬁnal concentration of 3 mM. The reaction
was stopped by the addition of 200 μL of 10% trichloroacetic acid.
Ouabain-insensitive ATPases were assayed under the same conditions
with the addition of 1mMouabain. Na+,K+-ATPase activity was calculat-
ed by the difference between the two assays. Released inorganic phos-
phate (Pi) was measured by the method of Chan et al. [40]. Enzyme-
speciﬁc activities were calculated as nmol Pi released/min/mg protein.
2.11. Reduced glutathione (GSH)andmalondialdehyde (MDA) concentrations
GSH concentrations were measured according to Browne and
Armstrong [41] with slightmodiﬁcations. Striatal homogenates contain-
ing 0.3–0.5 mg of protein were deproteinized with 7.5% metaphosphoricFig. 4. Effect of intrastriatal administration of ethylmalonic acid (EMA, 1.5 μmol) on glucose uti
mean ± SEM for 3–4 independent experiments (animals) per group. Glucose utilization (A) an
received intrastriatal NaCl injection (one-way ANOVA followed by the Duncan's multiple rangacid, centrifuged at 9.000 ×g for 10 min and the supernatant collected.
Thirty microliters of this supernatant was mixed with 185 μL of 100 mM
sodium phosphate buffer, pH 8.0, containing 5 mM EDTA, and 15 μL of
o-phthaldialdehyde (1 mg/mL). This mixture was incubated at room
temperature in a dark room for 15 min. Fluorescence was measured
using excitation and emission wavelengths of 350 nm and 420 nm,
respectively. Calibration curve was prepared with standard GSH (0.001–
1 mM) and the concentrations calculated as nmol GSH/mg protein.
MDA levels were measured according to the method described by
Yagi [42] modiﬁed slightly. Brieﬂy, 100 μL of 10% trichloroacetic acid
(TCA) and 200 μL of 0.67% thiobarbituric acid in 7.1% sodium sulfate
were added to 100 μL of supernatants containing 0.3–0.5 mg of protein
and incubated for 2 h in a boiling water bath. The mixture was allowed
to cool in on running tapwater for 5min. The resulting pink-stained com-
plex was extracted with 300 μL of butanol. Fluorescence of the organic
phase was measured using excitation and emission wavelengths of
515 nm and 553 nm, respectively. A calibration curve was performed
using 1,1,3,3-tetramethoxypropane and subjected to the same treatment
as supernatants. MDA levels were calculated as nmol MDA/mg protein
using a calibration curve determined with 1,1,3,3-tetramethoxypropane.lization and lactate production (B) in rat striatum 2 or 24 h after EMA injection. Values are
d lactate production (B) are expressed as μmol/h/g tissue. *p b 0.05 compared to rats that
e test).
Fig. 5. Effect of intrastriatal administration of ethylmalonic acid (EMA, 1.5 μmol) on
Na+,K+-ATPase activity in puriﬁed synaptic plasmamembranes from rat striatum 2 or 24 h
after EMA injection. Values are mean ± SEM for 4–6 independent experiments (animals)
performed in triplicate and are expressed as nmol Pi/min/mg protein. *p b 0.05 compared
to rats that received intrastriatal NaCl injection (one-way ANOVA followed by the
Duncan's multiple range test).
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Protein content of samples was measured by the method of Lowry
et al. [43] using bovine serum albumin as standard.
2.13. Statistical analysis
Data are expressed as means ± standard error of the mean (SEM) for
absolute values. Assays were performed in duplicate or triplicate and the
mean or median was used for statistical analysis. Results were analyzed
using the computerized statistical software SPSS 19 and comparisons
between the mean values were calculated using the unpaired Student's
t test and one-way analysis of variance (ANOVA) followed by the post-
hoc Duncan multiple range test when F was signiﬁcant. Differences
between groups were rated signiﬁcant at p b 0.05.
3. Results
3.1. EMA striatal concentrations
We ﬁrst determined the concentrations of EMA in the striatum 1 h
after a single acute intrastriatal injection of this organic acid (0.75 μmol
and 1.5 μmol). The mean striatal EMA concentrations were of the orderFig. 6. Dose-dependent effects of intrastriatal administration of ethylmalonic acid doses (EMA, 0.7
(D) activities in rat striatum24 h after EMA injection. Values aremean±SEM for 4 independent ex
(CS), nmol DCIP reducedmin/mg protein (complex II), nmol cytochrome c reducedmin/mg prote
that received intrastriatal NaCl injection (one-way ANOVA followed by the Duncan's multiple ranof 0.39 μmol/g (~0.48 mM) and 0.63 μmol/g (~0.78 mM), respectively.
EMA was not detected in striatum from NaCl-injected rats.
3.2. Intrastriatal EMA injection reduced CO2 production from glucose and
citrate synthase activity
We ﬁrst investigated the ex vivo effects of EMA on CO2 production
from glucose in striatum of young rats. We veriﬁed that glucose oxida-
tion was signiﬁcantly decreased both at 2 and 24 h after EMA injection
(30%, p b 0.05) (Fig. 1), suggesting a blockage of aerobic glycolysis
and/or CAC function. Next, we evaluated the effect of EMA administra-
tion on the activities of some CAC enzymes in mitochondrial prepara-
tions. We found a signiﬁcant reduction (18–22%, p b 0.05, Fig. 2A) of
CS activity both at 2 and at 24 h after EMA injection, indicating an im-
pairment of the CAC. In contrast, α-KGDH, SDH and MDH activities
were not changed by EMA injection (Fig. 2, panels B, C and D).
3.3. Intrastriatal EMA injection inhibited complexes II and II–III activities of
the ETC
The next experimentswere performed to assess the effect of EMA on
various ETC complexes. Fig. 3A shows that EMA signiﬁcantly inhibited
the activities of complex II (30%, p b 0.05) and complex II–III of the
ETC (20%, p b 0.05, Fig. 3B) only 24 h after its injection,without affecting
complex IV activity (Fig. 3C).
3.4. Intrastriatal injection of EMA increased glucose consumption and
lactate production
We also investigated the ex vivo effects of EMA on glucose and
lactate production from glucose in striatum from young rats in order
to evaluate whether this compound could induce anaerobic glycolysis.
We observed that glucose consumption was signiﬁcantly increased
2 h (up to 50%, p b 0.05) and 24 h after EMA injection (30%, p b 0.05)
(Fig. 4A). Simultaneous signiﬁcant increases of lactate production
were observed 2 and 24 h after EMA injection (up to 32%, p b 0.05)
(Fig. 4B). The data indicate that anaerobic glycolysis was stimulated
by EMA and is in accordance with our results showing a reduction of
14CO2 production and of CS and ETC complexes II and II–III activities.
3.5. Intrastriatal EMA injection did not change creatine kinase activity
Next, we evaluated the effects of EMA on CK activity in rat striatum
homogenates and observed that this enzyme activity was not modiﬁed
by EMA in vivo administration (data not shown). Since CK plays a key5 or 1.5 μmol) on citrate synthase (A), complex II (B), complex II–III (C) and Na+,K+-ATPase
periments (animals) performed in triplicate and are expressed as nmol TNB/min/mg protein
in (complex II–III) and nmol Pi/min/mg protein (Na+,K+-ATPase). *p b 0.05 compared to rats
ge test).
Table 1
In vitro effects of EMA (5 mM) on the activities of CS and complexes II and II–III in striatum
homogenates.
Enzyme activities Control 5 mM EMA
Citrate synthase 521.4 ± 31,87696 576.0 ± 18.8
Complex II 2.43 ± 0.50 3.14 ± 0.45
Complex II–III 6.96 ± 0.76 7.87 ± 0.41
Results are represented asmean+SEM(n=4) andexpressed as nmol TNB/min/mgprotein
(CS), as DCIP reduced min/mg protein (complex II) and as nmol cytochrome c reduced
min/mg protein (complex II–III). No signiﬁcant differences were observed (Student's t
test for paired samples).
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intracellular energy transfer is not mainly altered by EMA.3.6. Intrastriatal EMA injection inhibited synaptic Na+,K+-ATPase activity
We also evaluated the effects of EMA on Na+,K+-ATPase activity in
puriﬁed synapticmembranes, a critical enzyme necessary for themainte-
nance of cell membrane potential. Fig. 5 shows that intrastriatal injection
of EMA signiﬁcantly inhibited Na+,K+-ATPase activity (30%, p b 0.05) 2
and 24 h after EMA injection.3.7. Dose-dependent effects caused by intrastriatal administration of
distinct doses of EMA on CS, complexes II and III–III and Na+,K+-ATPase
activities
It can be seen in Fig. 6 that a lower dose EMA (0.75 μmol)was not able
to alter the activities of CS, the ETC complexes II and III–III and
Na+,K+-ATPase in striatum of rats 24 h after injection,whereas admin-
istration of 1.5 μmol EMA signiﬁcantly reduced these activities, as previ-
ously observed.3.8. EMA addition to striatum homogenates does not alter the activities of
CS and complexes II and II–III of the ETC
We also evaluated whether the addition of 5 mMEMA to cell super-
natants could decrease CS and complexes II and II–III activities. We
observed that under these in vitro conditions EMA did not alter the
activities of CS and complexes II and II–III, suggesting that this organic
acid does not have a direct effect on these enzymatic proteins (Table 1).Fig. 7. Effect of intrastriatal administration of ethylmalonic acid (EMA, 1.5 μmol) on GSH conce
mean ± SEM for 5–6 independent experiments (animals) and are expressed as nmol/mg prot
followed by the Duncan's multiple range test).3.9. Intrastriatal EMA injection diminished GSH and increased MDA
concentrations
EMA intrastriatal administration provoked a signiﬁcant reduction of
GSH concentrations (20%, p b 0.05, Fig. 7A) and an increase in MDA
levels (25%, p b 0.01, Fig. 7B) in the striatum of young rats only 24 h
after EMA injection, indicating a disruption of redox homeostasis.
3.10. Antioxidants were able to prevent Na+,K+-ATPase inhibition and GSH
reduction caused by intrastriatal EMA injection
Thenwe investigated the effects of the antioxidants NAC andMEL on
EMA-induced inhibition of the activity of Na+,K+-ATPase. NAC did not
modify the reduction of this enzyme activity (Fig. 8A), whereas MEL
completely prevented the inhibitory effect of EMAon this enzyme activity
(Fig. 8B).
We ﬁnally evaluated the effects of NAC on EMA-induced diminution
of GSH concentrations. Fig. 9 shows that NAC pre-treatment completely
abolished EMA-induced decrease of GSH concentration.
4. Discussion
The pathogenesis of the neurological dysfunction presented by
patients affected by EE and SCADD is still poorly known. However,
since some patients affected by EE and SCADD present intermittent
lactic acidosis and mitochondrial abnormalities on microscopy [9,16,
17,44,45], it indicatesmitochondrial dysfunction. This hypothesis is sup-
ported by experimental studies performed in human ﬁbroblasts and in
the liver of SCAD deﬁcient mice showing mitochondrial alterations of
energy and redox homeostasis [7,8]. However, the biochemical hallmark
of these disorders is the accumulation and high urinary excretion of
EMA that is produced at excessive amounts in tissues, particularly in
the liver, and possibly in the brain of the affected patients since fatty
acids are essential and can bemetabolized by the developingmammali-
an brain [46–48]. It is also presumed that EMA produced in the liver and
in other peripheral tissues may reach the brain, since short-chain fatty
acids including EMA can easily cross the blood–brain barrier [49–52].
Regarding to ETHE1 encephalopathy, it is well known that H2S, that
accumulates in this disorder, is neurotoxic, although we cannot rule
out that other neurotoxic agents, such as EMA, at high concentrations,
may also contribute to the encephalopathy characteristic of this disease.
Previous in vitro experimental studies performed in rat brain and in
human skeletal muscle showed that EMAmarkedly compromises bioen-
ergetics, besides inducing oxidative damage and decreasing antioxidantntrations (A) and MDA levels (B) in rat striatum 2 or 24 h after EMA injection. Values are
ein. *p b 0.05 compared to rats that received intrastriatal NaCl injection (one-way ANOVA
Fig. 9. Effect of N-acetylcysteine (NAC) on the reduction of GSH concentrations caused by
EMA intrastriatal injection. Animals received saline or NAC (50 mg/kg, 3 days, one injection
per day, i.p.) prior to intrastriatal injection of EMA (1.5 μmol) or saline. Data are presented
as mean ± SEM for 4–6 independent experiments (animals) performed in triplicate.
*p b 0.05 compared to rats pre-treated with saline and treated with NaCl; #p b 0.05,
compared to rats pre-treated with saline and treated with EMA (one-way ANOVA followed
by the Duncan's multiple range test).
Fig. 8. Effect of N-acetylcysteine (NAC, panel A) and melatonin (MEL, panel B) on the
inhibition of Na+,K+-ATPase activity caused by EMA intrastriatal injection. Animals received
saline or NAC (50mg/kg, 3 days, one injection per day, i.p.) prior to the intrastriatal injection
of EMA or NaCl. MEL (20mg/kg) was injected simultaneously with EMA (1.5 μmol) or NaCl.
Data are presented as mean± SEM for 4–6 independent experiments (animals) performed
in triplicate. *p b 0.05 compared to rats pre-treated with saline and treated with NaCl;
##p b 0.01, compared to rats pre-treated with saline and treated with EMA (one-way
ANOVA followed by the Duncan's multiple range test).
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53]. The humanand experimental animal studies reinforce the hypothesis
that disturbances inmitochondrial homeostasis possibly induced by EMA
accumulation play a role in the neuropathology of SCADD and EE. It is also
feasible that during episodes of metabolic decompensation that are char-
acterized by intense fatty acid and protein catabolism EMA tissue concen-
trations increase evenmore in these disorders andmay act synergistically
with other environmental factors such as fever provoking neurological
damage [2,7].
In this work, we showed for the ﬁrst time that in vivo intrastriatal
administration of EMA compromises mitochondrial energy and redox
homeostasis and markedly reduces the activity of a crucial enzyme
necessary for neurotransmission.
EMA intracerebral administration decreased CO2 production from
glucose and increased glucose consumption and lactate production in
the striatum, indicating a disturbance in the aerobic glycolytic pathway
and/or the CAC and stimulation of anaerobic glycolysis. Althoughwe did
not measure the activities of the enzymes of the glycolytic pathway, we
demonstrated that the activities of CS and of complexes II and II–III of
the ETC were signiﬁcantly inhibited by EMA in vivo injection. Our
present data may explain the lactic acidosis and mitochondrial micro-
scopic abnormalities found in tissues from SCADD and EE patients [3,
9,16,17,44]. It is unlikely that the reduction of these enzyme activities
involved in energy production by EMA was due to a diminution of
mitochondrial loss or viability since complex IV and other CAC enzyme
activities (KGDH, SDH and MDH) were not changed by EMA in vivo
administration. It is also conceivable that CAC blockage through CS
inhibition as well the reduction of the electron ﬂow through the ETCcould possibly explain the reduction of 14CO2 and the increase of glucose
utilization and lactate production as observed here.
On the other hand, it is unlikely that EMA directly attacked CS and
complexes II and II–III proteins inhibiting their activities since in vitro in-
cubation of striatum supernatants with this organic acid (5 mM) pro-
voked no changes of these activities. However, we cannot rule out the
possibility that in vivo EMA administration leads to ethylmalonyl-CoA
generation that could inhibit CS activity, as occurs with other fatty
acyl-CoA derivatives (butyryl-CoA, octanoyl-CoA, decanoyl-CoA
and palmitoyl-CoA) that inhibit CS in a dose-dependent way [54]. It
is also feasible that EMA-induced inhibitory effects could be second-
ary to the induction of oxidative stress (oxidative damage on CS and
the ETC complex proteins), as previously demonstrated in vitro for
this short-chain organic acid [53]. Our ﬁndings of increased lipid perox-
idation and reduction of GSH concentrations caused by intrastriatal
EMA administration support this hypothesis.
A previous study demonstrated a competition between succinate
and EMA for the same mitochondrial membrane carrier reducing mito-
chondrial succinate oxidation (complex II inhibition) [13]. Moreover,
EMA reduced in vitro the viability of striatal slices, measured by MTT
reduction, and synergisticallywith Ca2+ provokedmitochondrial swell-
ing in striatum of rats in vivo [14]. Therefore, our present in vivo data
showing EMA-induced reduction of the ETC ﬂow (impaired oxidative
phosphorylation) and disturbance of CAC via citrate synthase inhibition
probably leading to lower ATP synthesis in striatum of young rats is
consistent with the hypothesis that this short-chain organic acid
compromises mitochondrial bioenergetics in vivo.
We also found that the activity of creatine kinase that is crucial for
intracellular ATP transfer and buffering was not affected by intrastriatal
administration of EMA. This is in accordance with the ﬁndings of Ferreira
and coworkers [51] demonstrating that in vivo administration of EMAdid
not modify CK activity and suggest that energy transfer is not mainly
altered in striatum by EMA in vivo administration. Previous studies have
found inhibitory effects of EMA on CK activity in vitro [10,11]. However,
it should be stressed that in these reports the signiﬁcant effects were
obtained only at higher concentrations of EMA (2.5 mM–5.0) supple-
mented to the incubation medium. In our present investigation, we
obtained maximal levels of 0.78 mM of EMA in the striatum, but it must
be stressed that the supernatants used tomeasure CK activity were dilut-
ed approximately 100-fold, so that the ﬁnal concentrations of EMA in our
assays were of the order of 150 times lower than those employed in the
previously described in vitro studies. Thus, the apparently conﬂicting
results obtained in the present work and in the previous reports may
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the different concentrations of EMA present during the assays used to
measure CK activity. We would also like to point out that the injection
of a lower dose of EMA (0.75 μmol) was not able to change any of the
parameters evaluated, whereas the administration of a higher dose of
this organic acid (1.5 μmol) altered various parameters, demonstrating
a dose-dependent effect.
Another interesting ﬁnding of the present study was that intrastriatal
injection of EMA signiﬁcantly reducedNa+,K+-ATPase activity, which is a
crucial enzyme responsible for the generation of themembrane potential,
through the active transport of sodium and potassium ions in the CNS,
necessary to maintain neuronal excitability and cellular volume control.
This enzyme is present at high concentrations in the brain cellular mem-
brane, consuming about 40–50% of the ATP generated in this tissue [55,
56]. Maintenance of Na+,K+-ATPase activity is critical for normal brain
function, and reduction of its activity is related to neuronal damage in
the rat and human brain [57–60]. On the other hand, it was recently
reported that EMA does not modify the activity of Na+,K+-ATPase
in vitro, but its administration in vivo reduces the mRNA levels
(expression) of Na+,K+-ATPase [61]. Although we did not measure
Na+,K+-ATPase protein levels, ourﬁndings of a reduction of this enzyme
activity could be correlated with the reduction of Na+,K+-ATPase mRNA
levels presented by Schuck et al. [61]. It is of note that Na+,K+-ATPase is
vulnerable to oxidative damage, particularly through oxidation of sulfhy-
dryl or other essential groups of the enzyme, and through alteration of
membrane phospholipids by oxidation or by the interference of lipo-
philic substances [62–64]. Therefore, under our experimental condi-
tions intrastriatal administration of EMA could induce free radical
generation and promote oxidative attack in vulnerable groups of this
enzyme protein reducing its activity. This seems to be the case since
the antioxidant MEL completely abolished the inhibitory effect of EMA
on Na+,K+-ATPase. Thus, our present data suggest that EMA-induced
Na+,K+-ATPase occurred via oxidation possibly by hydroxyl radicals,
which are mainly scavenged by MEL [65–67].
This is also consistent with our present ﬁndings demonstrating that
in vivo intrastriatal injection of EMAdisturbed redox homeostasis, by sig-
niﬁcantly decreasing GSH concentrations and increasing the levels of
MDA (lipid peroxidation). Since endogenous GSH is the main naturally-
occurring antioxidant in the brain and is used to evaluate the non-
enzymatic antioxidant capacity of a tissue to prevent the damage
associated to free radical processes [66], it is concluded that EMA admin-
istration reduced the brain antioxidant defenses in vivo, compromising
the striatal redox homeostasis. It is also conceivable that the reduction
of GSH levels may result in increased reactive species generation and ox-
idation of proteins (Na+,K+-ATPase activity reduction) and lipids (in-
creased levels of MDA) elicited by EMA. This is in accordance with
previous studies demonstrating that EMA increases lipid and protein
damage in vitro in cerebral cortex of rats [53]. We also observed that
the administration ofNAC, that is able to generateGSH in the brain, totally
restored striatum GSH concentrations in EMA-injected rats.5. Conclusion
To summarize, we report for the ﬁrst time that in vivo intrastriatal
administration of EMA disturbs energy and redox homeostasis. We also
veriﬁed that Na+,K+-ATPase was markedly inhibited by EMA in vivo
injection probably through free radical generation. Since this enzyme is
critical for a normal neurotransmission and reduction of its activity is
related to neurodegeneration [57,59,60,68], and since mitochondrial
energy and redox homeostasis are necessary to normal brain function-
ing, we presume that these pathomechanisms may be involved in the
neurological dysfunction presented by the disorders inwhich EMA accu-
mulates. We also suggest that neuroprotective antioxidant compounds
like NAC and MEL may be useful as therapeutic adjuvants for the treat-
ment of these diseases.Acknowledgements
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